150 related articles for article (PubMed ID: 11991598)
1. p73 overexpression and nuclear accumulation in hepatitis C virus-associated hepatocellular carcinoma.
Zemel R; Koren C; Bachmatove L; Avigad S; Kaganovsky E; Okon E; Ben-Ari Z; Grief F; Ben-Yehoyada M; Shaul Y; Tur-Kaspa R
Dig Dis Sci; 2002 Apr; 47(4):716-22. PubMed ID: 11991598
[TBL] [Abstract][Full Text] [Related]
2. Absence of mutation of the p73 gene localized at chromosome 1p36.3 in hepatocellular carcinoma.
Mihara M; Nimura Y; Ichimiya S; Sakiyama S; Kajikawa S; Adachi W; Amano J; Nakagawara A
Br J Cancer; 1999 Jan; 79(1):164-7. PubMed ID: 10408709
[TBL] [Abstract][Full Text] [Related]
3. Overexpression but lack of mutation and methylation of p73 in hepatocellular carcinoma.
Pan H; Liao SJ; Lai WY; Lu HC; Hsiao KM
Acta Oncol; 2002; 41(6):550-5. PubMed ID: 12546528
[TBL] [Abstract][Full Text] [Related]
4. p73 is up-regulated in a subset of hepatocellular carcinomas.
Herath NI; Kew MC; Whitehall VL; Walsh MD; Jass JR; Khanna KK; Young J; Powell LW; Leggett BA; Macdonald GA
Hepatology; 2000 Mar; 31(3):601-5. PubMed ID: 10706549
[TBL] [Abstract][Full Text] [Related]
5. Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells.
Sayan AE; Sayan BS; Findikli N; Ozturk M
Oncogene; 2001 Aug; 20(37):5111-7. PubMed ID: 11526499
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of alterations in p73 gene, related to p53 at 1p36, in human hepatocellular carcinoma.
Aoki T; Miyamoto A; Marubashi S; Nagano H; Umeshita K; Fujiwara Y; Dono K; Nakamori S; Sakon M; Monden M
Int J Oncol; 2004 Feb; 24(2):441-6. PubMed ID: 14719122
[TBL] [Abstract][Full Text] [Related]
7. Quantitative TP73 transcript analysis in hepatocellular carcinomas.
Stiewe T; Tuve S; Peter M; Tannapfel A; Elmaagacli AH; Pützer BM
Clin Cancer Res; 2004 Jan; 10(2):626-33. PubMed ID: 14760085
[TBL] [Abstract][Full Text] [Related]
8. Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma.
Tannapfel A; Wasner M; Krause K; Geissler F; Katalinic A; Hauss J; Mössner J; Engeland K; Wittekind C
J Natl Cancer Inst; 1999 Jul; 91(13):1154-8. PubMed ID: 10393724
[TBL] [Abstract][Full Text] [Related]
9. Tumor-suppressor p53 gene in hepatitis C and B virus-associated human hepatocellular carcinoma.
Shieh YS; Nguyen C; Vocal MV; Chu HW
Int J Cancer; 1993 Jun; 54(4):558-62. PubMed ID: 8390407
[TBL] [Abstract][Full Text] [Related]
10. Genetic alternations of p73 are infrequent but may occur in early stage hepatocellular carcinoma.
Peng CY; Tsai SL; Yeh CT; Hung SP; Chen MF; Chen TC; Chu CM; Liaw YF
Anticancer Res; 2000; 20(3A):1487-92. PubMed ID: 10928060
[TBL] [Abstract][Full Text] [Related]
11. Dissection of cell context-dependent interactions between HBx and p53 family members in regulation of apoptosis: a role for HBV-induced HCC.
Knoll S; Fürst K; Thomas S; Villanueva Baselga S; Stoll A; Schaefer S; Pützer BM
Cell Cycle; 2011 Oct; 10(20):3554-65. PubMed ID: 22030623
[TBL] [Abstract][Full Text] [Related]
12. FUSE Binding Protein 1 Facilitates Persistent Hepatitis C Virus Replication in Hepatoma Cells by Regulating Tumor Suppressor p53.
Dixit U; Pandey AK; Liu Z; Kumar S; Neiditch MB; Klein KM; Pandey VN
J Virol; 2015 Aug; 89(15):7905-21. PubMed ID: 25995247
[TBL] [Abstract][Full Text] [Related]
13. Amphiregulin induces the alternative splicing of p73 into its oncogenic isoform DeltaEx2p73 in human hepatocellular tumors.
Castillo J; Goñi S; Latasa MU; Perugorría MJ; Calvo A; Muntané J; Bioulac-Sage P; Balabaud C; Prieto J; Avila MA; Berasain C
Gastroenterology; 2009 Nov; 137(5):1805-15.e1-4. PubMed ID: 19664633
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus core protein inhibits tumor suppressor protein promyelocytic leukemia function in human hepatoma cells.
Herzer K; Weyer S; Krammer PH; Galle PR; Hofmann TG
Cancer Res; 2005 Dec; 65(23):10830-7. PubMed ID: 16322229
[TBL] [Abstract][Full Text] [Related]
15. Expression and clinical significance of TAp73alpha, p53, PCNA and apoptosis in hepatocellular carcinoma.
Qin HX; Nan KJ; Yang G; Jing Z; Ruan ZP; Li CL; Xu R; Guo H; Sui CG; Wei YC
World J Gastroenterol; 2005 May; 11(18):2709-13. PubMed ID: 15884108
[TBL] [Abstract][Full Text] [Related]
16. Physical and functional interaction between HCV core protein and the different p73 isoforms.
Alisi A; Giambartolomei S; Cupelli F; Merlo P; Fontemaggi G; Spaziani A; Balsano C
Oncogene; 2003 May; 22(17):2573-80. PubMed ID: 12730672
[TBL] [Abstract][Full Text] [Related]
17. Expression of p53 and its homologues in primary and recurrent squamous cell carcinomas of the head and neck.
Weber A; Bellmann U; Bootz F; Wittekind C; Tannapfel A
Int J Cancer; 2002 May; 99(1):22-8. PubMed ID: 11948487
[TBL] [Abstract][Full Text] [Related]
18. Low MIB-1 labeling index in anti-HCV positive hepatocellular carcinoma.
Watanuki A; Ohwada S; Fukusato T; Kawate S; Makita F; Morishita Y
Int J Oncol; 1998 Nov; 13(5):1017-22. PubMed ID: 9772294
[TBL] [Abstract][Full Text] [Related]
19. Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma.
Koskinas J; Petraki K; Kavantzas N; Rapti I; Kountouras D; Hadziyannis S
J Viral Hepat; 2005 Nov; 12(6):635-41. PubMed ID: 16255765
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism of hepatocarcinogenesis.
Sheu JC
J Gastroenterol Hepatol; 1997 Oct; 12(9-10):S309-13. PubMed ID: 9407351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]